Naltrexone (Vivitrol) - A Once Monthly Injection for Alcoholism
An injectable extended-release formulation of the opioid-receptor antagonist naltrexone (Vivitrol - Alkermes/Cephalon) has been approved by the FDA for once-monthly use, along with psychosocial support, to maintain abstinence from alcohol. Naltrexone inhibits the rewarding effects of alcohol. Oral naltrexone (Revia, and others) has been approved for treatment of alcohol dependence since 1994, but poor adherence has limited its effectiveness. In the new extended-release (XR) formulation, naltrexone is encapsulated in polylactide-co-glycolide microspheres (similar to absorbable suture material) and placed in aqueous suspension for intramuscular (IM) injection....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Naltrexone (Vivitrol) - A Once Monthly Injection for Alcoholism
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1240
Article Code: 1240c
Date: July 31, 2006
Volume: 48
Pages: 62-64
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1240
Article Code: 1240c
Date: July 31, 2006
Volume: 48
Pages: 62-64
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)